proPSMA
Proved PSMA PET is far more accurate than conventional scans for staging, with less radiation.
302 men; accuracy 92% vs 65%; fewer equivocal findings; changed management in 28% vs 15%. Lancet 2020.
Setting
High-risk localised prostate cancer staging: PSMA PET/CT vs CT + bone scan
Phase
Phase 3
Sponsor
Peter MacCallum Cancer Centre / ANZUP
Registry
Headline result
Accuracy 92% vs 65%.
Reported
2020
Enrolled
302
Replication
Consistent with the OSPREY and CONDOR registrational studies for 18F-DCFPyL.
In plain words
What these results mean for people, not percentages
Accuracy for pelvic nodal or distant metastases (AUC)primaryother endpoint
- 92 vs 65 out of 100 reached this endpoint with PSMA PET/CT compared with CT + bone scan; 27 more per 100.
- Roughly one extra person helped for every 4 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
- The p-value (<0.0001) says a difference this large would rarely happen by chance; it does not say how large or how useful the difference is.
- This endpoint is not one of the standard survival or response measures; read it alongside the trial's primary result.
- These results apply to the people the trial enrolled: High-risk localised prostate cancer staging: PSMA PET/CT vs CT + bone scan. People in a different situation may not see the same effect.
- The trial selected people by a biomarker (PSMA); the result should not be assumed for people whose cancer does not have it.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
302 participants enrolled.
Accuracy for pelvic nodal or distant metastases (AUC)primary
· p <0.0001
PSMA PET/CT92 of 100
n = 150
CT + bone scan65 of 100
n = 152
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Accuracy for pelvic nodal or distant metastases (AUC)primary | PSMA PET/CT | 150 | 92% | — | <0.0001 | link |
| CT + bone scan | 152 | 65% |
Replication
Consistent with the OSPREY and CONDOR registrational studies for 18F-DCFPyL.